To date, no clear clinical evidence has been found to suggest the tumorigenic effect of GLP-1RAs (226), whereas plenty of studies have indicated that GLP-1RAs can inhibit the growth of ovarian, breast, prostate, and pancreatic cancer (227, 228)
Furthermore, clinical data shows patients who stop taking Semaglutide regain 2/3 of their weight within a year
Across the trials, when people stop the medication, the weight tends to come back, on the order of two-thirds of what was lost within a year
The presence of major pharmaceutical manufacturers, strong adoption of advanced therapeutic options, and extensive insurance coverage for prescription medicines further reinforced the regions dominant position
Within six months of treatment, grocery bills drop by more than five percent